

A practical guide for providers on helping patients find Latisse in stock. Includes 5 actionable steps, alternatives, and workflow tips for your practice.
One of the most common follow-up questions from patients prescribed Latisse (Bimatoprost 0.03%) is: "My pharmacy doesn't have it — what do I do?" As a prescriber, you're in a unique position to help patients navigate this challenge and ensure they can start or continue their eyelash growth treatment without unnecessary delays.
This guide provides practical, actionable steps your practice can take to help patients access Latisse or generic Bimatoprost, along with alternatives and workflow tips to streamline the process.
Latisse is not in a formal FDA-listed shortage. The availability challenges patients face are driven by:
For background on these dynamics, see our provider briefing on Latisse availability.
Understanding the patient experience helps you anticipate and address their frustrations:
Generic Bimatoprost 0.03% is therapeutically equivalent to brand-name Latisse and offers two major advantages for patients:
Unless a patient specifically requests brand-name Latisse or needs the included applicators, writing the prescription for generic Bimatoprost improves the likelihood of a smooth fill.
Recommend Medfinder to patients as a tool for checking real-time pharmacy availability. This simple step can save your patients hours of phone calls and pharmacy visits. Consider adding a Medfinder recommendation to your post-visit instructions or patient handouts.
If your practice doesn't already dispense Latisse, consider adding it. In-office dispensing:
Contact your AbbVie/Allergan representative for information on wholesale supply and the Allē loyalty program integration.
Set expectations about cost during the prescribing visit. Many patients don't realize insurance won't cover Latisse until they're at the pharmacy counter. Proactively discussing cost demonstrates empathy and helps patients prepare. Key points to share:
Direct patients to our savings guide for Latisse for detailed information.
Before sending the prescription, take a moment to confirm the patient's pharmacy carries Bimatoprost. Your staff can call ahead, or you can suggest pharmacies known to stock it. Independent pharmacies and pharmacies near dermatology or ophthalmology clusters are often better bets than large retail chains.
If Latisse or generic Bimatoprost truly isn't accessible, or if a patient is looking for different options, here are alternatives to discuss:
For a patient-facing resource on alternatives, share our article on alternatives to Latisse.
Small workflow changes can significantly improve the Latisse prescribing experience:
Develop a brief SOP for Latisse prescriptions that includes:
Ensure your front-desk and clinical staff can answer common patient questions about Latisse availability and cost. The most frequent questions are covered in our patient-facing shortage update.
Consider a follow-up call or message 1–2 weeks after prescribing to confirm the patient was able to fill their prescription. This catches patients who may have given up due to availability or cost barriers and gives you an opportunity to troubleshoot.
Latisse availability challenges are an ongoing reality of prescribing a cosmetic medication in a healthcare system designed around covered drugs. By prescribing generic Bimatoprost, leveraging tools like Medfinder, and proactively addressing cost and availability with patients, you can significantly improve treatment access and patient satisfaction.
For the companion patient guide, see how to find Latisse in stock. For cost-focused guidance, see our provider guide to helping patients save money on Latisse.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.